Health Trials

About this trial

The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.

Eligibility criteria

Qualifiers

Patients ≥ 18 years-old at time of consent.

Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).

Recipients of 7-8/8 related or unrelated HLA-matched or related haploidentical donor.

Peripheral blood stem cell graft

Disqualifiers

Recipient of CD34+ selected or engineered stem cell graft.

Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).

Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.

Pulmonary dysfunction with DLCO <50% corrected for hemoglobin

Trial design

Treatments tested in this trial

  • Belumosudil

Treatment groups

46 Participants
are divided into 1 treatment group

Locations

8
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)07920, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)11725, CommackNew York, United States

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov